Nature Reviews Drug Discovery contents August 2017 Volume 16 Number 8 pp 513-586

If you are unable to see the message below, click here to view.

Advertisement
See Things Differently Learn about Charles River's comprehensive imaging capabilities including PET, SPECT, MRI, MRS and autoradiography. Our PET services are supported by custom PET ligands available from a local cyclotron and novel methods like AIF. MRI offerings include pharmacological MRI to map response to drugs and magnetic resonance spectroscopy to measure metabolite changes.
TABLE OF CONTENTS
August 2017 Volume 16 Number 8		Advertisement
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis & Christian D. Klein	Genomics has met its match! MAKE MORE MEANINGFUL CONNECTIONS A powerful first-line phenotyping technology delivering a readout of the molecular phenotype and all its influences, both genetic and non-genetic. See how genomics and metabolomics are breaking through together.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
The National Institute on Drug Abuse is seeking a scientific executive with expertise in medications development, clinical trials, and the Food and Drug Administration's regulations to lead a preclinical and clinical research program focused on developing innovative treatment approaches for substance use disorders. For more information, please visit our website.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Technical Note: Simplify Production of Complex Proteins & Biologics Producing high quality, functional proteins in a rapid and cost-effective manner can be challenging when dealing with complex or difficult-to-express proteins, particularly if cGMP-compliance is needed. Find out how implementing the right expression platform can transform your efforts.  Download article now
Comment: Combination products: modernizing the regulatory paradigm Nina L. Hunter & Rachel E. Sherman p513 | doi:10.1038/nrd.2017.66 New opportunities to develop innovative — and often complex — products that combine drugs, devices and/or biological components are rapidly emerging, raising questions about how such products should be regulated. Here, we discuss the ongoing efforts of the FDA to develop a modern, transparent, flexible and consistent science-based regulatory approach for combination products. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Calls grow to tap the gold mine of human genetic knockouts Asher Mullard p515 | doi:10.1038/nrd.2017.139 A Human Knockout Project would systematically search for loss-of-function genetic mutations in humans to help uncover new drug targets. PDF
NEWS IN BRIEF FDA approvals for the first 6 months of 2017 Asher Mullard p519 | doi:10.1038/nrd.2017.148 PDF
FDA approves first new sickle cell drug in 20 years Asher Mullard p519 | doi:10.1038/nrd.2017.149 PDF
New cancer vaccines show clinical promise Asher Mullard p519 | doi:10.1038/nrd.2017.150 PDF
BIOBUSINESS BRIEFS Market watch: Strategies for biosimilars in emerging markets Ajay Gautam p520 | doi:10.1038/nrd.2017.113 PDF
BIOBUSINESS BRIEFS Patent watch: Supreme Court decision favours biosimilars Courtenay C. Brinckerhoff p521 | doi:10.1038/nrd.2017.136 PDF
AN AUDIENCE WITH Joshua Gordon p523 | doi:10.1038/nrd.2017.134 Joshua Gordon, Director of the National Institute of Mental Health, discusses the evolving RDoC framework for research into mental illnesses, and the appropriate balance between the funding of basic and clinical research. PDF
FROM THE ANALYST'S COUCH Colorectal cancer drugs market Sorcha Cassidy & Basharut A. Syed p525 | doi:10.1038/nrd.2017.59 The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs. PDF
RESEARCH HIGHLIGHTS Top Infectious diseases: Decrypting Cryptosporidium p527 | doi:10.1038/nrd.2017.147 PDF Muscle disorders: FGF19 reduces muscle wasting p528 | doi:10.1038/nrd.2017.132 PDF Anticancer therapy: Neutrophils deliver the goods p528 | doi:10.1038/nrd.2017.133 PDF Cancer: RNA-based approaches target KRAS p529 | doi:10.1038/nrd.2017.137 PDF Infectious diseases: Soil-sifting snags new antibiotic p530 | doi:10.1038/nrd.2017.141 PDF IN BRIEF Cardiovascular disease: CRHR2 blockade prevents heart failure | Type 2 diabetes: Broccoli extract lowers glucose levels | Neurodegenerative disorders: SRC-ABL inhibitors protect motor neurons | Cancer: mRNA-encoded bispecific antibodies eliminate tumours PDF Drug discovery JOBS of the week Drug discovery project leaders Servier PhD Student Positions and Postdoctoral Position on Antimicrobial Drug Discovery Purdue University Sr. investigator / Investigator III, Drug Discovery in Liver Diseas at China Novartis Institutes for Biomedical Research (CNIBR) China Novartis Institutes for Biomedical Research (CNIBR) Molecular Pathology Research Laboratory Head - Cancer Research / Biomarkers and Translational Research (M / F) Boehringer Ingelheim Postdoctoral Fellow - Parasitology - at the University of Sao Paulo University of Sao Paulo, Brazil More Science jobs from Drug discovery EVENT 3rd world congress on pharmaceutics and drug discovery 15.12.17 Dubai, UAE More science events from
Advertisement
Nature Milestones: Interactive antibody timeline  Nature Milestones: Antibodies presents an interactive timeline on the history of antibodies covering everything from their initial description in antisera through to their application in immunotherapy. The timeline includes written content, video interviews and animations.  Access the timeline free online
PERSPECTIVES		Top
OPINION Opportunities and challenges in phenotypic drug discovery: an industry perspective John G. Moffat, Fabien Vincent, Jonathan A. Lee, Jörg Eder & Marco Prunotto p531 | doi:10.1038/nrd.2017.111 There has been a resurgence in interest in phenotypic drug discovery (PDD) approaches in recent years based on their potential to address the incompletely understood complexity of diseases and their promise of delivering first-in-class drugs. However, PDD approaches can also present considerable challenges, and this article focuses on the lessons learned by researchers engaged in PDD in the pharmaceutical industry, and discusses how PDD can best deliver value to drug discovery portfolios. Abstract | Full Text | PDF
Advertisement
Focus on Disease models: reproducibility and translation  Lab Animal, a Nature Research journal focusing on in vivo methods, research and technology with model organisms of human health & disease, presents a special Focus on reproducibility and translation of in vivo research with disease models.  Access this Focus > Produced with support from:  Taconic Biosciences, Inc.  Charles River
REVIEWS		Top
Breaking barriers to novel analgesic drug development Ajay S. Yekkirala, David P. Roberson, Bruce P. Bean & Clifford J. Woolf p545 | doi:10.1038/nrd.2017.87 Existing pain therapies are often inadequate or associated with side effects. Here, Woolf and colleagues discuss new and existing strategies for the development of improved pain therapeutics, highlighting key challenges and considerations in the clinical development of novel analgesics. Abstract | Full Text | PDF
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis & Christian D. Klein p565 | doi:10.1038/nrd.2017.33 Flaviviruses, including dengue and Zika viruses, are of substantial public health concern. Klein and colleagues review the development of broad-spectrum antiviral agents that would target many of the known and potentially unknown flaviviruses. The benefits and caveats of molecules that target either viral proteins or host mechanisms exploited by these viruses are discussed. Abstract | Full Text | PDF | Supplementary information
Corrigendum: Upcoming market catalysts in Q3 2017 Sonny Nghiem p586 | doi:10.1038/nrd.2017.138 Full Text | PDF
Advertisement
Open for Submissions  npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota. Explore the benefits of submitting your manuscript.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.